ENDRA Life Sciences Inc. found using ticker (NDRA) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 6 and 3.5 calculating the mean target price we have 5.17. Given that the stocks previous close was at 0.71 this now indicates there is a potential upside of 628.2%. The 50 day MA is 0.8 and the 200 day MA is 0.84. The company has a market capitalisation of $24m. Company Website: http://www.endrainc.com
The potential market cap would be $173m based on the market concensus.
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person’s body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
